Fulcrum Therapeutics announced the pricing of its underwritten public offering of common stock and pre-funded warrants.
The gross proceeds from the offering are expected to be $175.0 million before deducting underwriting discounts and commissions.
The company intends to use the net proceeds primarily for general corporate purposes, including working capital, research and development expenses, and potential acquisitions.
Offering Details
11,851,853 shares of common stock priced at $13.50 per share and pre-funded warrants for 1,111,193 shares at $13.499 per warrant.
Underwriters
J.P. Morgan, Leerink Partners, Cantor, Oppenheimer & Co., and Truist Securities are acting as book-running managers for the offering.
Closing Date
The offering is expected to close on or about December 11, 2025.
- Fulcrum Therapeutics aims to utilize the funds for research and development, including clinical trials and platform enhancement.
- The offering signifies investor interest in the company's potential to address rare diseases with small molecules.
- The involvement of reputable book-running managers enhances the credibility of the offering.
The successful pricing of the public offering indicates confidence in Fulcrum Therapeutics' vision and potential for addressing rare diseases through innovative drug development.